Value
7.6/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 7.8 |
| Analyst target | 7.5 |
- ▸Attractively valued
PRCT · Why this verdict
Why PROCEPT BioRobotics (PRCT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
The stock is in a falling-knife pattern: a death cross is confirmed, the moving average slope is declining at negative 9.1% per 30 days, volume surged 2.4 times the average on the most recent selloff, and RSI stands at 35, all indicating that the price decline is accelerating rather than stabilizing. Chart pattern detection | The 200-day moving average slope turns positive within 4 months, indicating the longer-term decline is reversing. | →Stable |
| CounterRSI at 35 is approaching oversold territory; in a high-growth medical device company, this level of technical weakness occasionally precedes sharp recoveries when the fundamental story reasserts itself. | ||
Revenue grew 20% year-over-year and the moat score is 7.2 out of 10, which is meaningfully above average, suggesting that the robotic surgical platform has real switching costs or clinical differentiation that can sustain growth even as the stock declines. Growth breakdown | Revenue growth remains above 15% year-over-year in each of the next 2 reported quarters. | →Stable |
| Counter20% growth from a small base in medical robotics does not guarantee durability; competitive entrants from established surgical robotics companies could challenge the platform's market position. | ||
The business burns cash at negative 13% of revenue and quality scores only 3.2 out of 10, meaning the company is not yet generating positive returns on the capital invested despite reaching 20% revenue growth, which raises questions about the timeline to profitability. Quality breakdown | Free cash flow burn as a percentage of revenue narrows to below 5% within the next 2 annual reporting periods as scale benefits kick in. | →Stable |
| CounterEarly-stage medical robotics companies typically run negative cash flow during commercial ramp; gross margins of the business are meaningful and the cash burn rate should compress with scale. | ||
Short interest stands at 12% of float and implied volatility is elevated at 131%, indicating that a significant portion of sophisticated market participants are bearish and that large price swings are expected around future news events. Key risks | Short interest falls below 7% of float over the next 6 months as the bull thesis gains traction and bears cover. | →Stable |
| CounterHigh short interest combined with a strong moat score and revenue growth trajectory creates a potential short squeeze catalyst if the next earnings result surprises positively on revenue or cash burn improvement. | ||
The stock is in a falling-knife pattern: a death cross is confirmed, the moving average slope is declining at negative 9.1% per 30 days, volume surged 2.4 times the average on the most recent selloff, and RSI stands at 35, all indicating that the price decline is accelerating rather than stabilizing.
→StableChart pattern detection
- Expectation
- The 200-day moving average slope turns positive within 4 months, indicating the longer-term decline is reversing.
CounterRSI at 35 is approaching oversold territory; in a high-growth medical device company, this level of technical weakness occasionally precedes sharp recoveries when the fundamental story reasserts itself.
Revenue grew 20% year-over-year and the moat score is 7.2 out of 10, which is meaningfully above average, suggesting that the robotic surgical platform has real switching costs or clinical differentiation that can sustain growth even as the stock declines.
→StableGrowth breakdown
- Expectation
- Revenue growth remains above 15% year-over-year in each of the next 2 reported quarters.
Counter20% growth from a small base in medical robotics does not guarantee durability; competitive entrants from established surgical robotics companies could challenge the platform's market position.
The business burns cash at negative 13% of revenue and quality scores only 3.2 out of 10, meaning the company is not yet generating positive returns on the capital invested despite reaching 20% revenue growth, which raises questions about the timeline to profitability.
→StableQuality breakdown
- Expectation
- Free cash flow burn as a percentage of revenue narrows to below 5% within the next 2 annual reporting periods as scale benefits kick in.
CounterEarly-stage medical robotics companies typically run negative cash flow during commercial ramp; gross margins of the business are meaningful and the cash burn rate should compress with scale.
Short interest stands at 12% of float and implied volatility is elevated at 131%, indicating that a significant portion of sophisticated market participants are bearish and that large price swings are expected around future news events.
→StableKey risks
- Expectation
- Short interest falls below 7% of float over the next 6 months as the bull thesis gains traction and bears cover.
CounterHigh short interest combined with a strong moat score and revenue growth trajectory creates a potential short squeeze catalyst if the next earnings result surprises positively on revenue or cash burn improvement.
TrendMatrix Research · core thesis
Engine thesis — one sentence
PROCEPT BioRobotics is a growth-stage medical robotics company posting 20% revenue growth but in a confirmed falling-knife technical setup with a death cross, momentum score of only 3.0, volume surges on selloffs, and below-floor quality at 3.2 out of 10, making it a high-risk situation despite 30% analyst upside to target.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
3.2/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 8.8 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 6.3 |
| FCF quality | 0.0 |
| Moat | 7.2 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -13% of revenue
Growth
7.6/10data confidence 33%| Component | Sub-score |
|---|---|
| Rev growth | 7.6 |
- ▸Strong growth: 20% YoY
Momentum
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.0 |
| MACD | 2.7 |
| OBV | 10.0 |
| MA position | 1.0 |
| Volume | 3.2 |
- ▸Capitulation risk (RSI 26, below 200MA)
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -7.2%/30d — confirmed downtrend
Sentiment
7.2/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.0 |
| Price target | 9.3 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (10.0) — signal dampened
- ▸Analyst upside: 44%
Insider
5.0/10data confidence 50%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 5.1 |
- ▸Negligible insider selling — $28,479 (0.002% of mkt cap)
Peer rank
3.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.5 |
| quality rank | 1.6 |
| growth rank | 6.9 |
Technical
5.3/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.4 |
| support resistance | 8.9 |
| 52w position | 0.0 |
| gap | 5.0 |
Risk (lower is worse)
3.6/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.1 |
| days to cover | 5.1 |
| volatility | 0.0 |
| put call | 0.0 |
| implied vol | 0.0 |
| beta | 7.8 |
| debt equity | 9.1 |
- ▸Elevated put/call: 2.17
- ▸High IV: 100%
Catalyst
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (7)
- ASYMMETRY:1.7>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:38d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:4.0<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (0)
none
Reward-to-Risk
1.66
Upside
+24.9%
Downside
15.0%
Sizing output
AVOID
SetupFalling Knife — Death cross, below all MAs, RSI 26, MACD bearish
EdgeInst Constrain — Small cap ($1.2B) below institutional reach
SuitabilitySpeculative — Drawdown -68% (>40% off 52w high)
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Value at 7.6 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:4.0<4.5.
The strongest dimensions are Value at 7.6, Growth at 7.6, and Sentiment at 7.2; the weakest are Peer rank at 3.0, Quality at 3.2, and Risk (lower is worse) at 3.6. The V9 engine flagged 2 failed gates, producing an asymmetric reward-to-risk of 1.66 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Falling Knife Technical Setup
Trip ifThe 200-day moving average slope remains below negative 7% per 30 days for more than 4 consecutive months.
- P2Revenue Growth Moat Foundation
Trip ifRevenue growth falls below 10% year-over-year in any reported quarter over the next 4 quarters.
- P3Cash Burn Below Quality Floor
Trip ifFree cash flow burn exceeds 20% of revenue in any reported annual period over the next 12 months.
- P4Short Interest And Iv Risk
Trip ifShort interest rises above 18% of float at any point over the next 6 months.